We are very sad to announce the death of our director, Dr. David Seldin, MD, PhD. For further detail, please see Tribute to Dr. David Seldin.
In honor of Dr. Seldin, the Boston University Amyloidosis Center has established a fund to support the training of students and young investigators, a cause that was close to his heart. If you would like to make a gift in memory of Dr. Seldin, please see our donation page and indicate you would like your donation to go to the “David C. Seldin, MD, PhD Amyloid Research Training Award.”
The Amyloidosis Center at Boston University School of Medicine and Boston Medical Center, previously under the direction of David C. Seldin, M.D., Ph.D., is recognized internationally as a leader in basic and clinical research on amyloidosis and related diseases. The Center is unique in its approach, combining laboratory and clinical research to support exceptional care for patients with all forms of systemic amyloidosis.
Our mission is to serve as a:
- Coordinating center for clinical trials and laboratory research on systemic amyloidosis.
- Referral center for evaluation and treatment of patients with amyloid diseases
- Reference laboratory for amyloid pathology and molecular diagnostics
- Resource for information on amyloidosis for scientists, physicians, patients, and their families
Activities in the Alan and Sandra Gerry Amyloid Research Laboratory at Boston University School of Medicine are directed by Lawreen Connors, Ph.D. and include the Amyloidosis Reference Laboratory as well as basic research on amyloidosis, in collaboration with other laboratories at Boston University and elsewhere.
The Amyloidosis Clinical Program under the direction of John Berk, M.D. coordinates the multidisciplinary evaluation of patients with amyloidosis by subspecialists who are expert in amyloid diseases. The Clinical Program works closely with the Stem Cell Transplant Program in the Section of Hematology-Oncology, Department of Medicine, directed by Vaishali Sanchorawala, M.D., and with the Clinical Trials Office. Trials and treatment are available for all major forms of amyloidosis.